81 related articles for article (PubMed ID: 19243244)
1. Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma.
Quan WD; Quan FM
Cancer Biother Radiopharm; 2009 Feb; 24(1):1-6. PubMed ID: 19243244
[TBL] [Abstract][Full Text] [Related]
2. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
[TBL] [Abstract][Full Text] [Related]
3. High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma.
Quan W; Ramirez M; Taylor WC; Vinogradov M; Khan N; Jackson S
Cancer Biother Radiopharm; 2004 Dec; 19(6):770-5. PubMed ID: 15665626
[TBL] [Abstract][Full Text] [Related]
4. High-dose continuous infusion plus pulse interleukin-2 and famotidine in metastatic kidney cancer.
Quan W; Ramirez M; Taylor C; Vinogradov M; Quan F; Khan N
Cancer Biother Radiopharm; 2005 Feb; 20(1):36-40. PubMed ID: 15778577
[TBL] [Abstract][Full Text] [Related]
5. Continuous infusion interleukin-2 and intravenous famotidine in metastatic melanoma.
Quan WD; Milligan KS; Quan FM; Cuenca RE; Khan N; Liles DK; Walker PR
Cancer Biother Radiopharm; 2006 Dec; 21(6):607-12. PubMed ID: 17257076
[TBL] [Abstract][Full Text] [Related]
6. Continuous infusion interleukin-2 and famotidine in metastatic kidney cancer.
Quan WD; Vinogradov M; Quan FM; Khan N; Liles DK; Walker PR
Cancer Biother Radiopharm; 2006 Oct; 21(5):515-9. PubMed ID: 17105423
[TBL] [Abstract][Full Text] [Related]
7. Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma.
Quan W; Knupp C; Quan F; Walker P
Cancer Biother Radiopharm; 2010 Apr; 25(2):179-83. PubMed ID: 20423231
[TBL] [Abstract][Full Text] [Related]
8. High-dose intensity pulse interleukin-2 with famotidine has activity in metastatic melanoma.
Quan WD; Walker PR; Picton M; Quan FM; King LA; Tyre C; Liles DK
Cancer Biother Radiopharm; 2008 Oct; 23(5):641-6. PubMed ID: 18999936
[TBL] [Abstract][Full Text] [Related]
9. Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
Quan WD; Quan FM; King LA; Walker PR
Cancer Biother Radiopharm; 2008 Feb; 23(1):108-13. PubMed ID: 18298334
[TBL] [Abstract][Full Text] [Related]
10. Outpatient intravenous interleukin-2 with famotidine has activity in metastatic melanoma.
Quan WD; Quan FM; Perez M; Johnson E
Cancer Biother Radiopharm; 2012 Sep; 27(7):442-5. PubMed ID: 22731929
[TBL] [Abstract][Full Text] [Related]
11. Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer.
Quan WD; Gagnon GA; Walker PR; Quan FM
Cancer Biother Radiopharm; 2011 Feb; 26(1):65-7. PubMed ID: 21348776
[TBL] [Abstract][Full Text] [Related]
12. Activity of outpatient intravenous interleukin-2 and famotidine in metastatic clear cell kidney cancer.
Quan WD; Quan FM
Cancer Biother Radiopharm; 2014 Mar; 29(2):58-61. PubMed ID: 24251758
[TBL] [Abstract][Full Text] [Related]
13. Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over.
Quan W; Ramirez M; Taylor C; Quan F; Vinogradov M; Walker P
Cancer Biother Radiopharm; 2005 Feb; 20(1):11-5. PubMed ID: 15778574
[TBL] [Abstract][Full Text] [Related]
14. High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer.
Quan WD; Quan FM
Cancer Biother Radiopharm; 2009 Apr; 24(2):181-3. PubMed ID: 19409039
[TBL] [Abstract][Full Text] [Related]
15. Repeated cycles with 72-hour continuous infusion interleukin-2 in kidney cancer and melanoma.
Quan W; Brick W; Vinogradov M; Taylor WC; Khan N; Burgess R
Cancer Biother Radiopharm; 2004 Jun; 19(3):350-4. PubMed ID: 15285881
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
17. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.
Bar MH; Sznol M; Atkins MB; Ciobanu N; Micetich KC; Boldt DH; Margolin KA; Aronson FR; Rayner AA; Hawkins MJ
J Clin Oncol; 1990 Jul; 8(7):1138-47. PubMed ID: 2358835
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
[TBL] [Abstract][Full Text] [Related]
19. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic melanoma: a phase II trial of the Cancer Biotherapy Research Group (formerly the National Biotherapy Study Group).
Dillman RO; Wiemann MC; VanderMolen LA; Bury MJ; DePriest C; Church C
Cancer Biother Radiopharm; 1997 Aug; 12(4):249-55. PubMed ID: 10851472
[TBL] [Abstract][Full Text] [Related]
20. Nursing care of patients receiving high-dose, continuous-infusion interleukin-2 with pulse dose and famotidine.
Tyre CC; Quan W
Clin J Oncol Nurs; 2007 Aug; 11(4):513-9. PubMed ID: 17723964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
